CL2017000563A1 - Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia. - Google Patents

Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia.

Info

Publication number
CL2017000563A1
CL2017000563A1 CL2017000563A CL2017000563A CL2017000563A1 CL 2017000563 A1 CL2017000563 A1 CL 2017000563A1 CL 2017000563 A CL2017000563 A CL 2017000563A CL 2017000563 A CL2017000563 A CL 2017000563A CL 2017000563 A1 CL2017000563 A1 CL 2017000563A1
Authority
CL
Chile
Prior art keywords
elsiglutide
induced diarrhea
treat gastrointestinal
gastrointestinal mucositis
includes chemotherapy
Prior art date
Application number
CL2017000563A
Other languages
English (en)
Inventor
Ruben Giorgino
Simona Roncoroni
Selma Calcagnile
Fabio Trento
Riccardo Spezia
Cecilia Moresino
Carsten Boye Knudsen
Original Assignee
Helsinn Healthcare Sa
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Healthcare Sa, Zealand Pharma As filed Critical Helsinn Healthcare Sa
Publication of CL2017000563A1 publication Critical patent/CL2017000563A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>LA INVENCIÓN SE RELACIONA AL USO DE ELSIGLUTIDA PARA PREVENIR O REDUCIR LA OCURRENCIA DE DAÑO GASTROINTESTINAL CAUSADO POR AGENTES QUIMIOTERAPÉUTICOS, INCLUYENDO MUCOSITIS GASTROINTESTINAL Y DIARREA INDUCIDA POR QUIMIOTERAPIA (CID).</p>
CL2017000563A 2014-09-10 2017-03-08 Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia. CL2017000563A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462048520P 2014-09-10 2014-09-10

Publications (1)

Publication Number Publication Date
CL2017000563A1 true CL2017000563A1 (es) 2017-09-29

Family

ID=54548212

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000563A CL2017000563A1 (es) 2014-09-10 2017-03-08 Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia.

Country Status (18)

Country Link
US (1) US20160067311A1 (es)
EP (1) EP3191115A1 (es)
JP (1) JP2017532308A (es)
KR (1) KR20170052661A (es)
CN (1) CN107073081A (es)
AR (1) AR103119A1 (es)
AU (1) AU2015313919A1 (es)
BR (1) BR112017004577A2 (es)
CA (1) CA2959110A1 (es)
CL (1) CL2017000563A1 (es)
EA (1) EA201790552A1 (es)
IL (1) IL250928A0 (es)
MA (1) MA40623A (es)
MX (1) MX2017003166A (es)
PH (1) PH12017500426A1 (es)
SG (1) SG11201701690WA (es)
TW (1) TW201613634A (es)
WO (1) WO2016038455A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170087216A1 (en) * 2015-09-17 2017-03-30 Helsinn Healthcare Sa Therapeutic Uses of Elsiglutide
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
AU2018285580B2 (en) * 2017-06-16 2024-05-09 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues
AU2020454132A1 (en) * 2020-06-19 2023-02-02 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
CN115054683B (zh) * 2022-05-19 2023-06-09 唐颢 胰高血糖素样肽-2在制备缓解阿霉素心脏毒性药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200709027B (en) * 2005-04-22 2009-01-28 Novacea Inc Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin D compounds or mimics thereof
NZ593050A (en) * 2005-05-04 2012-12-21 Zealand Pharma As Glucagon-like-peptide-2 (glp-2) analogues
EP2314616A1 (en) * 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists

Also Published As

Publication number Publication date
US20160067311A1 (en) 2016-03-10
PH12017500426A1 (en) 2017-07-31
CA2959110A1 (en) 2016-03-17
EP3191115A1 (en) 2017-07-19
TW201613634A (en) 2016-04-16
EA201790552A1 (ru) 2017-08-31
MA40623A (fr) 2016-03-17
JP2017532308A (ja) 2017-11-02
SG11201701690WA (en) 2017-04-27
WO2016038455A1 (en) 2016-03-17
AU2015313919A1 (en) 2017-03-16
CN107073081A (zh) 2017-08-18
AR103119A1 (es) 2017-04-19
MX2017003166A (es) 2017-06-19
IL250928A0 (en) 2017-04-30
BR112017004577A2 (pt) 2018-01-23
KR20170052661A (ko) 2017-05-12

Similar Documents

Publication Publication Date Title
UY37381A (es) Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
CL2018001790A1 (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este (divisional solicitud 201602748)
CO2018013557A2 (es) Composiciones que comprenden cepas bacterianas
CL2017003142A1 (es) Composiciones que comprenden cepas bacterianas
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CL2017001393S1 (es) Automovil
CU20190006A7 (es) Composiciones para inhibir masp-3
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
BR112019012343A2 (pt) anticorpos il-11ra
MX2022002026A (es) Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos.
EA201691916A1 (ru) Биарильные ингибиторы киназы
CL2017000563A1 (es) Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia.
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
CR20170230A (es) Anticuerpos anti-cd79b y métodos de uso
EA201790649A1 (ru) Бензилзамещенные индазолы в качестве ингибиторов bub 1
CL2017001185S1 (es) Automovil
CL2017000792A1 (es) Derivados del ácido borónico
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
CO2017000416A2 (es) Una composición hidráulica
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CR20170005A (es) Derivados de insoindolina
UY37153A (es) Sulfonilamidas sustituidas para combatir parásitos animales
UY37472A (es) Sulfonilamidas sustituidas para combatir parásitos animales
CL2019000049A1 (es) Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil).